TAL1 Antibody (E-4): sc-365527
- TAL1 Antibody (E-4) is a mouse monoclonal IgM κ provided at 200 µg/ml
- specific for an epitope mapping between amino acids 306-331 at the C-terminus of TAL1 of human origin
- recommended for detection of TAL1 of mouse, rat and human origin by WB, IP, IF and ELISA; also reactive with additional species, including and canine and bovine
- TransCruz reagent for ChIP application (sc-365527 X, 200 µg/0.1 ml)
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for TAL1 Antibody (E-4). This work is in progress.
QUICK LINKS
TAL1 Antibody (E-4) is a mouse monoclonal IgM antibody that detects TAL1 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). TAL1, also known as SCL, is a crucial transcription factor that plays a significant role in embryonic hematopoiesis, regulating the development of blood cells. TAL1 forms heterodimers with other proteins, such as E2A and HEB/HTF4, to bind to specific DNA sequences known as E-boxes, which are essential for the transcriptional regulation of genes involved in hematopoietic differentiation. TAL1′s importance in hematopoiesis is underscored by involvement in T cell acute lymphoblastic leukemia, where TAL1 activation is observed in up to 60% of cases, highlighting a key role in leukemogenesis. Additionally, TAL1 interaction with casein kinase IIalpha, a serine/threonine protein kinase, can significantly enhance activity, thereby accelerating the leukemogenic process. Anti-TAL1 antibody (E-4) serves as an invaluable tool for researchers studying the mechanisms of hematopoiesis and the pathogenesis of related disorders.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
TAL1 Antibody (E-4) References:
- Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells. | Martelli, AM., et al. 2014. Adv Biol Regul. 56: 6-21. PMID: 24819383
- The origin of relapse in pediatric T-cell acute lymphoblastic leukemia. | Vicente, C. and Cools, J. 2015. Haematologica. 100: 1373-5. PMID: 26521295
- Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update. | Evangelisti, C., et al. 2018. Int J Mol Sci. 19: PMID: 29949919
- Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia. | Bayón-Calderón, F., et al. 2020. Int J Mol Sci. 21: PMID: 33081391
- Nuclear PFKP promotes CXCR4-dependent infiltration by T cell acute lymphoblastic leukemia. | Gao, X., et al. 2021. J Clin Invest. 131: PMID: 34255748
- MicroRNAs as Modulators of the Immune Response in T-Cell Acute Lymphoblastic Leukemia. | Del Gaizo, M., et al. 2022. Int J Mol Sci. 23: PMID: 35055013
- TAL1 cooperates with PI3K/AKT pathway activation in T-cell acute lymphoblastic leukemia. | Thielemans, N., et al. 2022. Haematologica. 107: 2304-2317. PMID: 35354248
- Silencing LCN2 enhances RSL3-induced ferroptosis in T cell acute lymphoblastic leukemia. | Tian, C., et al. 2023. Gene. 879: 147597. PMID: 37390872
- Suppression of super-enhancer-driven TAL1 expression by KLF4 in T-cell acute lymphoblastic leukemia. | Noura, M., et al. 2024. Oncogene. 43: 447-456. PMID: 38102337
- Single-cell CRISPR screening characterizes transcriptional deregulation in T-cell acute lymphoblastic leukemia. | Meyers, S., et al. 2024. Haematologica. 109: 3167-3181. PMID: 38813729
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TAL1 Antibody (E-4) | sc-365527 | 200 µg/ml | $322.00 | |||
TAL1 (E-4) Neutralizing Peptide | sc-365527 P | 100 µg/0.5 ml | $69.00 | |||
TAL1 Antibody (E-4) X | sc-365527 X | 200 µg/0.1 ml | $322.00 |